Literature DB >> 24966927

Expression patterns of podocyte-associated mRNAs in patients with proliferative or non-proliferative glomerulopathies.

Patrícia Garcia Rodrigues1, Rafael Nazário Bringhenti2, Jonathan Frapporti do Nascimento1, Gabriel Joelsons1, Mariane dos Santos1, Sane Pereira1, Francisco Veríssimo Veronese3.   

Abstract

AIM: It is not clear how the podocyte damage manifests in different glomerulopathies. This study evaluated the podocyte-associated mRNA profiles in renal tissue and urine of patients with proliferative (PGs) or non-proliferative (NPGs) glomerulopathies.
METHODS: Messenger RNA levels of nephrin, podocin, podocalyxin, synaptopodin, and alpha-actinin-4 were measured in the kidney tissue and urinary cells by real-time polymerase chain reaction. Podocyte-associated mRNAs were correlated with proteinuria and renal function, and the effect of immunosuppressive treatment of PGs and NPGs on urine mRNAs was assessed up to one year of follow up.
RESULTS: Podocyte-associated mRNAs were expressed consistently less in kidney tissue from patients with NPGs, and urinary podocyte mRNA levels were significantly higher in the PG group. After six months of immunosuppressive therapy, patients with PGs showed a significant reduction in the expression of podocin, podocalyxin, and alpha-actinin-4 compared with baseline (p<0.001). In the NPG group, alpha-actinin-4 levels decreased (p=0.008), and there was also a trend toward reduced podocalyxin mRNA (p=0.08). Urine podocyte-associated mRNAs correlated with the level of proteinuria at baseline and at six months, and there was a trend toward an inverse correlation between urinary mRNAs and kidney function at one year of follow up.
CONCLUSIONS: Podocyte-associated mRNAs were inhibited in kidney tissue concomitantly with their increase in urine in these patients with glomerulopathies. Different profiles of mRNA expression were seen, pointing to a higher degree of intra-renal podocytopenia in the NPGs and of podocyturia in the PGs. The immunosuppressive therapy effectively reduced the urinary levels of podocyte-associated mRNAs.

Entities:  

Keywords:  Glomerulopathy; nephrin; podocalyxin; podocin; podocyte; proteinuria

Mesh:

Substances:

Year:  2014        PMID: 24966927      PMCID: PMC4069963     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  42 in total

Review 1.  Podocyte damage damages podocytes: autonomous vicious cycle that drives local spread of glomerular sclerosis.

Authors:  Iekuni Ichikawa; Ji Ma; Masaru Motojima; Taiji Matsusaka
Journal:  Curr Opin Nephrol Hypertens       Date:  2005-05       Impact factor: 2.894

Review 2.  The podocyte's response to injury: role in proteinuria and glomerulosclerosis.

Authors:  S J Shankland
Journal:  Kidney Int       Date:  2006-05-10       Impact factor: 10.612

3.  Altered ultrastructural distribution of nephrin in minimal change nephrotic syndrome.

Authors:  Annika Wernerson; Fredrik Dunér; Erna Pettersson; Silwa Mengarelli Widholm; Ulla Berg; Vesa Ruotsalainen; Karl Tryggvason; Kjell Hultenby; Magnus Söderberg
Journal:  Nephrol Dial Transplant       Date:  2003-01       Impact factor: 5.992

4.  Comparative effects of plasmapheresis and intravenous cyclophosphamide on urinary podocyte excretion in patients with proliferative Lupus nephritis.

Authors:  T Nakamura; C Ushiyama; M Hara; S Osada; K Ugai; N Shimada; K Hayashi; I Ebihara; H Koide
Journal:  Clin Nephrol       Date:  2002-02       Impact factor: 0.975

5.  Nephrin redistribution on podocytes is a potential mechanism for proteinuria in patients with primary acquired nephrotic syndrome.

Authors:  S Doublier; V Ruotsalainen; G Salvidio; E Lupia; L Biancone; P G Conaldi; P Reponen; K Tryggvason; G Camussi
Journal:  Am J Pathol       Date:  2001-05       Impact factor: 4.307

6.  Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria.

Authors:  T Nakamura; C Ushiyama; S Osada; M Hara; N Shimada; H Koide
Journal:  Metabolism       Date:  2001-10       Impact factor: 8.694

7.  Expression of the slit-diaphragm protein, nephrin, in experimental diabetic nephropathy: differing effects of anti-proteinuric therapies.

Authors:  Darren J Kelly; Petri Aaltonen; Alison J Cox; Jon R Rumble; Robyn Langham; Sianna Panagiotopoulos; George Jerums; Harry Holthöfer; Richard E Gilbert
Journal:  Nephrol Dial Transplant       Date:  2002-07       Impact factor: 5.992

8.  Advances in the biology and genetics of the podocytopathies: implications for diagnosis and therapy.

Authors:  Laura Barisoni; H William Schnaper; Jeffrey B Kopp
Journal:  Arch Pathol Lab Med       Date:  2009-02       Impact factor: 5.534

9.  WINPEPI (PEPI-for-Windows): computer programs for epidemiologists.

Authors:  Joseph H Abramson
Journal:  Epidemiol Perspect Innov       Date:  2004-12-17

10.  Messenger RNA levels of podocyte-associated proteins in subjects with different degrees of glucose tolerance with or without nephropathy.

Authors:  Jonathan Fraportti do Nascimento; Luis H Canani; Fernando Gerchman; Patricia G Rodrigues; Gabriel Joelsons; Mariane dos Santos; Sane Pereira; Francisco V Veronese
Journal:  BMC Nephrol       Date:  2013-10-08       Impact factor: 2.388

View more
  5 in total

1.  Podocyte-associated mRNA profiles in kidney tissue and in urine of patients with active lupus nephritis.

Authors:  Mariane dos Santos; Rafael N Bringhenti; Patrícia G Rodrigues; Jonathan F do Nascimento; Sane V Pereira; Rafael Zancan; Odirlei A Monticielo; Andrese A Gasparin; Waldir P de Castro; Francisco V Veronese
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

2.  The nephroprotective action of Passiflora edulis in streptozotocin-induced diabetes.

Authors:  Ony Araújo Galdino; Iago de Souza Gomes; Renato Ferreira de Almeida Júnior; Maria Imaculada Conceição Ferreira de Carvalho; Bento João Abreu; Marcela Abbott Galvão Ururahy; Barbara Cabral; Silvana Maria Zucolotto Langassner; Karla Simone Costa de Souza; Adriana Augusto de Rezende
Journal:  Sci Rep       Date:  2022-10-20       Impact factor: 4.996

3.  The PD-1/PD-L1 Inhibitory Pathway is Altered in Primary Glomerulonephritides.

Authors:  Ewelina Grywalska; Iwona Smarz-Widelska; Ewelina Krasowska-Zajac; Izabela Korona-Glowniak; Karolina Zaluska-Patel; Michal Mielnik; Martyna Podgajna; Anna Malm; Jacek Rolinski; Wojciech Zaluska
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2017-08-02       Impact factor: 4.291

4.  CTLA-4 Expression Inversely Correlates with Kidney Function and Serum Immunoglobulin Concentration in Patients with Primary Glomerulonephritides.

Authors:  Ewelina Grywalska; Iwona Smarz-Widelska; Sebastian Mertowski; Krzysztof Gosik; Michał Mielnik; Martyna Podgajna; Monika Abramiuk; Bartłomiej Drop; Jacek Roliński; Wojciech Załuska
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2019-06-08       Impact factor: 4.291

5.  PD-1 and PD-L1 Expression on Circulating Lymphocytes as a Marker of Epstein-Barr Virus Reactivation-Associated Proliferative Glomerulonephritis.

Authors:  Ewelina Grywalska; Iwona Smarz-Widelska; Izabela Korona-Głowniak; Sebastian Mertowski; Krzysztof Gosik; Anna Hymos; Jarosław Ludian; Paulina Niedźwiedzka-Rystwej; Jacek Roliński; Wojciech Załuska
Journal:  Int J Mol Sci       Date:  2020-10-27       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.